Compare Agilent Technologies Inc (A) vs Icl Group Ltd (ICL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Agilent Technologies Inc vs Icl Group Ltd — how do they compare? Agilent Technologies Inc trades at $149.35 (market cap $42.00B), while Icl Group Ltd trades at $5.3 (market cap $6.94B). The key difference: Agilent Technologies Inc is far larger — about 6.1× Icl Group Ltd's market cap, and Icl Group Ltd pays the higher dividend (3.86%). Which is the better fit depends on your goals.
| A | ICL | |
|---|---|---|
Market Cap | $42.00B | $6.94B |
Sector | Health | Basic Materials |
52-Week High | $157.20 | $6.84 |
52-Week Low | $110.24 | $4.80 |
Enterprise Value | $43.55B | $9.57B |
Dividend Yield | 0.69% | 3.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $145.97, up 3.28% in the last session, with a bullish technical outlook from moving averages but overbought RSI levels. The company reported strong Q1 2026 earnings, beating estimates with EPS of $1.49, and maintains solid profitability with a net income margin of 19.55%. Recent developments include FDA and EU approvals for diagnostic assays and the acquisition of Biocare Medical, enhancing its healthcare portfolio.
The stock offers upside to the consensus price target of $154.90, supported by analyst optimism (77.5% buy ratings), but high valuation ratios like a P/E of 146.56 pose risks. Investors should monitor execution of growth initiatives and competitive pressures in the life sciences sector, with earnings on August 26, 2026, as a key catalyst.
ICL trades at $5.31, up 0.76% today, with a bullish technical signal from moving averages and strong Q2 2026 earnings beats. The company reported $7.15B revenue in 2025, with net income of $226M, and maintains a P/E of 22.13 and P/S of 0.89. Recent news highlights Q2 sales growth driven by potash and bromine prices, alongside a cost-transformation program.
Outlook is mixed: earnings momentum and dividend payments offer support, but declining profit margins and 100% hold analyst consensus indicate caution. Key risks include raw material cost volatility and geopolitical factors affecting the specialty minerals market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Agilent Technologies Inc
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →About Icl Group Ltd
ICL Group Ltd is a manufacturer of products based on minerals. The firm is comprised of four segments: phosphate solutions, potash, industrial products, and innovative agriculture solutions (IAS). These segments all contribute to the company's development of agriculture, food, and engineered material products and services. The company mines and manufactures potash and phosphates to be used as ingredients in fertilizers and serve as a component in the pharmaceutical and food additives industries. It is also engaged in industrial additives and materials, including flame retardants, phosphate salts, specialty phosphate blends, purified phosphoric acid, electronic-grade specialty phosphoric acids. Its geographical segments are Europe, Asia, North & South America, and the Rest of the world.
Read more on ICL →
